BioClinica partnership to support 'continuum of pharmacovigilance services'

By Melissa Fassbender contact

- Last updated on GMT

Bioclinica is actively partnering to provide innovative offering models and technologies. (Image: iStock/zakokor)
Bioclinica is actively partnering to provide innovative offering models and technologies. (Image: iStock/zakokor)
BioClinica and ArisGlobal have partnered to offer customers a comprehensive pharmacovigilance service as "one size fits all" model evolves.

As part of the agreement, BioClinica becomes ArisGlobal’s preferred partner in business process consulting and change management as sponsors implement or upgrade ARISg, ArisGlobal’s pharmacovigilance and clinical safety system.

The cloud-based solution helps facilitate drug development and regulatory compliance throughout the entire product life cycle.

We decided to partner with ArisGlobal because we saw the opportunity to offer a continuum of pharmacovigilance services that can fit the needs of sponsors and CROs as those needs change, whether sponsors are growing, merging, experiencing a surge or a drop in safety events​,” Mukhtar Ahmed, BioClinica President eHealth Solutions​, told “In the same way that therapies are moving from a ‘one size fits all’ model, so is our offering model​.”

According to the company, the partners are currently working to develop ArisGlobal’s next generation of products, which will combine medical knowledge with technologies derived from such areas as artificial intelligence, machine learning, and natural language processing.

BioClinica benefits by offering solutions that fit the evolving needs of sponsors, thereby becoming a trusted provider across the research landscape​,” added Ahmed.

Bioclinica is actively partnering​ to provide innovative offering models and technologies. Ahmed told us, “You can expect to see new partners and members of our App xChange throughout the year as we build our program to provide value to sponsors​.”

Related news

Show more

Related products


Process Development for Lyophilized Products

Baxter BioPharma Solutions | 30-Oct-2017 | Application Note

Baxter approaches formulation and process development with the intention of identifying the failure points for the product. Knowing where the product fails...


Advancing therapeutics for myeloma

Recipharm AB | 04-Sep-2017 | Case Study

Multiple myeloma is the second most common blood cancer in the world and despite survival rates increasing over the last decade, there remains a requirement...

Related suppliers